Lates News

The German biotechnology company CureVac announced on August 8th local time that CureVac and GlaxoSmithKline have reached agreements with BioNTech and Pfizer to resolve and dismiss all pending patent lawsuits related to mRNA-based COVID-19 vaccines in the United States, and to establish a framework for resolving patent disputes outside the United States. Under the terms of the agreement, CureVac and GlaxoSmithKline will receive a total of $740 million in payments, as well as single-digit royalties on future sales of the COVID-19 vaccine in the United States. In addition, CureVac will also receive a $50 million licensing fee for the use of their products in the United States from GlaxoSmithKline.